ArticleCancer immunology research2021
Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Article in Cancer immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Whole-body CD8Nature communications · 2025Trial
- Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers.Molecular cancer · 2026Article
- Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters.Theranostics · 2026Article
- The regulation of reporter transgene expression for diverse biological imaging applications.Npj imaging · 2025Review
- Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.European journal of nuclear medicine and molecular imaging · 2024Article
- Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression.Nature biomedical engineering · 2024Article
- Article
- CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.Nature reviews. Clinical oncology · 2024Review
- Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.Frontiers in immunology · 2024Article
- AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.Cancer immunology research · 2023Article
- Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.Journal of visualized experiments : JoVE · 2023Article
- Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.Theranostics · 2023Article
- Applying a clinical lens to animal models of CAR-T cell therapies.Molecular therapy. Methods & clinical development · 2022Review
- SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity.Scientific reports · 2022Article
- CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.Molecular therapy oncolytics · 2022Review
- Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology.International journal of molecular sciences · 2022Review
- Prospective approaches to enhancing CAR T cell therapy for glioblastoma.Frontiers in immunology · 2022Review
- PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies.Molecular imagingReview
- PET Imaging for Monitoring Cellular and Immunotherapy of Cancer.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 2 institutions in 2 countries.
Funding
Abstract
Although chimeric antigen receptor T (CART)-cell therapy has been successful in treating certain hematologic malignancies, wider adoption of CART-cell therapy is limited because of minimal activity in solid tumors and development of life-threatening toxicities, including cytokine release syndrome (CRS). There is a lack of a robust, clinically relevant imaging platform to monitor
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.